{"filing":{"accession_number":"0001213900-26-063185","cik":"0001514183","ticker":"SILO","company_name":"Silo Pharma, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"ea0292702-8k_silo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026063185/ea0292702-8k_silo.htm"},"events":[{"id":7853,"run_id":6890,"accession_number":"0001213900-26-063185","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The filing discloses a 1-for-15 reverse stock split effective June 2, 2026, which materially affects the capital structure and share count (from ~16.267 million to ~1.084 million shares outstanding). While reverse splits are sometimes routine capital management actions, this event is material to investors as it affects share price, voting power, and equity award calculations. The disclosure does not fit the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or delisting notice), making \"other_material\" the most appropriate classification.","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3227,"accession_number":"0001213900-26-063185","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a 1-for-15 reverse stock split effective June 2, 2026, which materially affects the capital structure and share count (from ~16.267 million to ~1.084 million shares outstanding). While reverse splits are sometimes routine capital management actions, this event is material to investors as it affects share price, voting power, and equity award calculations. The disclosure does not fit the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or delisting notice), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:54.711472+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3227,"accession_number":"0001213900-26-063185","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a 1-for-15 reverse stock split effective June 2, 2026, which materially affects the capital structure and share count (from ~16.267 million to ~1.084 million shares outstanding). While reverse splits are sometimes routine capital management actions, this event is material to investors as it affects share price, voting power, and equity award calculations. The disclosure does not fit the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or delisting notice), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:54.711472+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-06-01"}]}